Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Whipple

Internal Medicine Las Vegas, NV Medical Doctor

NPI 1427073824 CMS profile 19447

7473 W Lake Mead Blvd Ste 213, Las Vegas, NV 89128

Open in the dashboard

General payments

$1,450

84 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Whipple of Las Vegas, NV is reported in the CMS Open Payments database as having received $1,450 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $152 4
2024 General $16 1
2023 General $70 4
2022 General $420 22
2021 General $270 17
2020 General $275 19
2019 General $246 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Whipple
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Whipple were reported at $152. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Whipple Internal Medicine median Middle half National median
2019 $246 $159 $48–$570 $163
2020 $275 $119 $33–$402 $114
2021 $270 $135 $37–$521 $132
2022 $420 $141 $42–$496 $149
2023 $70 $149 $45–$519 $160
2024 $16 $154 $47–$537 $164
2025 $152 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $215 12 payments
  2. SK Life Science, Inc. $152 4 payments
  3. Novo Nordisk Inc $129 9 payments
  4. Pfizer Inc. $118 7 payments
  5. Novartis Pharmaceuticals Corporation $116 8 payments
  6. Astellas Pharma US Inc $111 6 payments
  7. AbbVie, Inc. $75 5 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $74 3 payments
  9. AstraZeneca Pharmaceuticals LP $59 5 payments
  10. Kowa Pharmaceuticals America, Inc. $54 3 payments
  11. Other $346 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,450 84 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $185 10 payments
  2. Ozempic $129 9 payments
  3. NURTEC ODT $112 5 payments
  4. MYRBETRIQ $111 6 payments
  5. ENTRESTO $99 7 payments
  6. RYBELSUS $84 6 payments
  7. CHANTIX $78 5 payments
  8. Livalo $54 3 payments
  9. Seglentis $54 3 payments
  10. Dayvigo $53 3 payments
  11. Other $600 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

220

Median for Internal Medicine: 777

Drug cost

$17,448

Median for Internal Medicine: $73,373

Branded share of claims

16.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 25 $15,166
Pantoprazole Sodium Generic 16 $488
Triamcinolone Acetonide Generic 12 $404
Levothyroxine Sodium Generic 26 $259
Atorvastatin Calcium Generic 34 $222
Propranolol Hcl Er Propranolol Hcl Brand 12 $202
Amlodipine Besylate Generic 27 $185
Gabapentin Generic 14 $173
Azithromycin Generic 16 $95
Metoprolol Succinate Generic 14 $94

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$24,257

Medicare's payments for the services billed

Medicare patients

77

Average age 75

Services billed

270

41 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 68%
Diabetes 62%
Chronic kidney disease 60%
Arthritis 52%
Ischemic heart disease 49%
Heart failure 45%
Atrial fibrillation 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record